Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT).

Full DD Report for INNT

You must become a subscriber to view this report.


Recent News from (NASDAQ: INNT)

Innovate Biopharmaceuticals Announces Presentation at the BIO-Europe Conference, Copenhagen 2018 - 24th Annual Partnering Conference
RALEIGH, N.C., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Innovate) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, today announced it intends to present at the BIO-Europe C...
Source: GlobeNewswire
Date: November, 05 2018 09:14
Innovate Biopharmaceuticals Announces Participation at the Jefferies 2018 London Healthcare Conference
RALEIGH, N.C., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, today announced it intends to present at ...
Source: GlobeNewswire
Date: October, 31 2018 09:00
Stronger than expected earnings lead stocks higher premarket
Red Hat (NYSE: RHT ) +49%  on being acquired by IBM. More news on: Red Hat, Inc., Diana Containerships Inc., China Recycling Energy Corporation, Stocks on the move, , Top stock market news, Read more ...
Source: SeekingAlpha
Date: October, 29 2018 09:27
Innovate Bio up 12% premarket on positive data on lead candidate
Micro cap Innovate Biopharmaceuticals (NASDAQ: INNT ) is up  12%  premarket on modest volume on the heels of its announcement of encouraging preclinical data on lead candidate larazotide acetate in a mouse NASH model. The data showed a positive effect on reducing gut barrier perm...
Source: SeekingAlpha
Date: October, 29 2018 08:23
Innovate Biopharmaceuticals Announces Positive Effect of Larazotide Acetate on reducing Intestinal Permeability in a NASH Preclinical Study
Top line results showed larazotide having a significant effect on intestinal permeability, a mechanism thought to be key for bacterial translocation leading to NAFLD/NASH Further preclinical data in combination with approved drugs in development for NASH liraglutide (VICTOZA ® ) ...
Source: GlobeNewswire
Date: October, 29 2018 07:00
Innovate Biopharmaceuticals to Host Clinical and Scientific Update Event on Thursday, September 6, 2018, in New York City.
RALEIGH, N.C., Sept. 06, 2018 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, plans to host an event on Thursday, September 6, 2018, in New York fr...
Source: GlobeNewswire
Date: September, 06 2018 07:30
Midday Gainers / Losers (09/04/2018)
Gainers:  MNKD +57% . NCTY +29% . TA +29% . REPH +21% . CADC +20% . CDZI +18% . KNSA +16% . EPIX +15% . INNT +14% . NBEV +13% . More news on: MannKind Corporation, The9 Limited, TravelCenters of America LLC, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: September, 04 2018 12:42
Today's Research Reports on Stocks to Watch: Innovate Biopharmaceuticals and TapImmune
NEW YORK, NY / ACCESSWIRE / September 4, 2018 / Both Innovate Biopharmaceuticals and TapImmune sprang to life on Friday seeing big gains after the companies announced plans to present at conferences this month. RDI Initiates Coverage on: Innovate Biopharmaceuticals, Inc. https://rdi...
Source: ACCESSWIRE IA
Date: September, 04 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-146.136.116.205.95400,396

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-14393,368620,41263.4043Short
2018-12-13147,798243,42160.7170Short
2018-12-1261,321129,11947.4918Short
2018-12-11245,060349,37670.1422Short
2018-12-10667,0201,159,27257.5378Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on INNT.


About Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT)

Logo for Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT)

Action Sports Camera and Memory Device Sales

 

Contact Information

 

 

Current Management

  • David H. Clarke / CEO
  • David Olert / CFO
  • Steven Barre / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • Jonathan Clark /
  • Robert B. Machinist / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • Christopher Miner / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member

Current Share Structure

  • Market Cap: $390,770,453 - 05/17/2018
  • Authorized: 350,000,000 - 04/06/2018
  • Issue and Outstanding: 25,691,680 - 04/06/2018

 



Daily Technical Chart for (NASDAQ: INNT)

Daily Technical Chart for (NASDAQ: INNT)


Stay tuned for daily updates and more on (NASDAQ: INNT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: INNT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in INNT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of INNT and does not buy, sell, or trade any shares of INNT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/